The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was highly similar to Stelara.

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

AD109 is a once daily pill that consists of aroxybutynin, an antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor.

Brekiya consists of dihydroergotamine mesylate, an ergotamine derivative, in a single-dose autoinjector for subcutaneous administration.

The Teal Wand is an at-home vaginal self-collection device intended to test for 14 types of high-risk HPV that have the highest risk for causing cervical cancer.

The patient's medical history included obesity, asthma, possible sleep apnea, and a potentially deviated septum.

HealthDay News — Drug overdose deaths decreased by 26.9% from 2023 to 2024, according to provisional data released today from the National Center for Health Statistics.

RxDx assay as a companion diagnostic to identify c-Met protein expression in non-squamous NSCLC patients eligible for treatment with Emrelis.

The prescription device is a wearable belt that includes a motor designed to transmit low amplitude, high frequency vibration ...

The Food and Drug Administration (FDA) has approved Optison ™ (perflutren protein-type A microsphere) injectable suspension for use in pediatric patients with suboptimal echocardiograms to opacify the ...

Nature Made, CeraVe, and Neutrogena placed No. 1 in three or more categories for best OTC product. The companies with the most No. 1 products were Haleon (23), Kenvue Inc. (17), Prestige Consumer ...

Order expected to affect specific medications covered under Medicare that are administered in a health care setting.